The SGLT2 inhibitor empagliflozin reduces mortality in experimental pulmonary hypertension

被引：0
|
作者：
Chowdhury, B. [1 ]
Luu, V. Z. [1 ]
Luu, A. Z. [1 ]
Kabir, M. G. [1 ]
Pan, Y. [1 ]
Teoh, H. [1 ]
Quan, A. [1 ]
Mazer, C. D. [2 ]
Verma, S. [1 ]
机构：
[1] St Michaels Hosp, Cardiac Surg, Toronto, ON, Canada
[2] St Michaels Hosp, Anesthesia, Toronto, ON, Canada
来源：
EUROPEAN HEART JOURNAL | 2019年 / 40卷
基金：
加拿大健康研究院;
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
56
引用
收藏
页码：11 / 11
页数：1
相关论文
共 50 条
  • [1] The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension
    Chowdhury, Biswajit
    Luu, Albert Z.
    Luu, Vincent Z.
    Kabir, M. Golam
    Pan, Yi
    Teoh, Hwee
    Quan, Adrian
    Sabongui, Sandra
    Al-Omran, Mohammed
    Bhatt, Deepak L.
    Mazer, C. David
    Connelly, Kim A.
    Verma, Subodh
    Hess, David A.
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2020, 524 (01) : 50 - 56
  • [2] The SGLT2 inhibitor, empagliflozin reduces early progressive proteinuria in obese SS rats
    Ekperikpe, Ubong
    Daniels, Jacori
    Mandal, Sautan
    Cooper, Jonita
    Johnson, Tyler
    Safir, Sarah
    Cornelius, Denise
    Williams, Jan
    PHYSIOLOGY, 2023, 38
  • [3] ADVERTISEMENT Jardiance (SGLT2 inhibitor, Empagliflozin). Indications
    不详
    TIDSSKRIFT FOR DEN NORSKE LAEGEFORENING, 2022, 142 (09) : 756 - 756
  • [4] THE SGLT2 INHIBITOR EMPAGLIFLOZIN REDUCES TISSUE SODIUM CONTENT IN PATIENTS WITH CHRONIC HEART FAILURE
    Kolwelter, Julie
    Kannenkeril, Dennis
    Linz, Peter
    Jung, Susanne
    Nagel, Armin M.
    Bosch, Agnes
    Ott, Christian
    Bramlage, Peter
    Uder, Michael
    Achenbach, Stephan
    Schmieder, Roland
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 585 - 585
  • [5] SGLT2 inhibitor empagliflozin: finally at the latter stage of understanding?
    Chan, Gary C. W.
    Tang, Sydney C. W.
    KIDNEY INTERNATIONAL, 2018, 93 (01) : 22 - 24
  • [6] THE SGLT2 INHIBITOR EMPAGLIFLOZIN DOES NOT EXHIBIT PRO THROMBOTIC EFFECTS
    Santos-Gallego, Carlos G.
    Zafar, Mohammad
    Antonio, Rodolfo San
    Ibanez, Juan Antonio Requena
    Botifa, Maria Belen Picatoste
    Ishikawa, Kiyotake
    Watanabe, Shin
    Hajjar, Roger
    Fuster, Valentin
    Badimon, Juan
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (11) : 1852 - 1852
  • [7] The SGLT2 inhibitor Empagliflozin shown to reduce hospitalizations for heart failure
    Idris, Iskandar
    DIABETES OBESITY & METABOLISM, 2016, 18 (01): : 110 - 110
  • [8] A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans
    Michel, Martin C.
    Mayoux, Eric
    Vallon, Volker
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2015, 388 (08) : 801 - 816
  • [9] The SGLT2 inhibitor empagliflozin attenuates atherosclerosis progression by inducing autophagy
    Hualin Xu
    Jie Fu
    Qiang Tu
    Qingyun Shuai
    Yizhi Chen
    Fuyun Wu
    Zheng Cao
    Journal of Physiology and Biochemistry, 2024, 80 : 27 - 39
  • [10] Biotransformation and mass balance of the SGLT2 inhibitor empagliflozin in healthy volunteers
    Chen, Lin-Zhi
    Jungnik, Arvid
    Mao, Yanping
    Philip, Elsy
    Sharp, Dale
    Unseld, Anna
    Seman, Leo
    Woerle, Hans-Juergen
    Macha, Sreeraj
    XENOBIOTICA, 2015, 45 (06) : 520 - 529
12345